ABO21009
Rheumatoid Arthritis (RA)
Key Facts
About AboleIIs Pharma
AbolerIS Pharma, founded in 2019, is a Belgian-French biotech focused on transforming the treatment of autoimmune diseases and transplant rejection through immune tolerance restoration. The company's core technology targets the CD45RC marker to selectively deplete pathogenic effector T and B cells while sparing regulatory T cells, aiming for long-term, drug-free remission. Backed by notable European life science VCs and having secured non-dilutive grants, AbolerIS has advanced its lead candidate ABO21009 into Phase 1 clinical trials, with initial data demonstrating a novel and potentially safer mechanism of action.
View full company profileAbout AboleIIs Pharma
AbolerIS Pharma, founded in 2019, is a Belgian-French biotech focused on transforming the treatment of autoimmune diseases and transplant rejection through immune tolerance restoration. The company's core technology targets the CD45RC marker to selectively deplete pathogenic effector T and B cells while sparing regulatory T cells, aiming for long-term, drug-free remission. Backed by notable European life science VCs and having secured non-dilutive grants, AbolerIS has advanced its lead candidate ABO21009 into Phase 1 clinical trials, with initial data demonstrating a novel and potentially safer mechanism of action.
View full company profileAbout AboleIIs Pharma
AbolerIS Pharma, founded in 2019, is a Belgian-French biotech focused on transforming the treatment of autoimmune diseases and transplant rejection through immune tolerance restoration. The company's core technology targets the CD45RC marker to selectively deplete pathogenic effector T and B cells while sparing regulatory T cells, aiming for long-term, drug-free remission. Backed by notable European life science VCs and having secured non-dilutive grants, AbolerIS has advanced its lead candidate ABO21009 into Phase 1 clinical trials, with initial data demonstrating a novel and potentially safer mechanism of action.
View full company profileAbout AboleIIs Pharma
AbolerIS Pharma, founded in 2019, is a Belgian-French biotech focused on transforming the treatment of autoimmune diseases and transplant rejection through immune tolerance restoration. The company's core technology targets the CD45RC marker to selectively deplete pathogenic effector T and B cells while sparing regulatory T cells, aiming for long-term, drug-free remission. Backed by notable European life science VCs and having secured non-dilutive grants, AbolerIS has advanced its lead candidate ABO21009 into Phase 1 clinical trials, with initial data demonstrating a novel and potentially safer mechanism of action.
View full company profileTherapeutic Areas
Other Rheumatoid Arthritis (RA) Drugs
| Drug | Company | Phase |
|---|---|---|
| GlyHealth Biomarkers | Avenna | Pre-clinical/Validation |
| SOL-116 | Lipum | Phase 1 |
| MYMD-1® | TNF Pharmaceuticals | Phase 2 |
| Telitacicept | Vor Biopharma | Marketed |